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The effect of dose scheduling on the pharmacodynamics of simulated human doses of cipro-
floxacin (200 mg intravenously [iv) every 12 h) and azlocillin (4 g iv every 12 h) alone or in
combination against Pseudomonas aeruginosa was studied in a two-compartment in vitro kinetic
model of infection. Studies with the two drugs in combination were compared using simulta-
neous or staggered (first doses of each drug were administered 6 h apart) dosing schedules.
Bacterial regrowth and resistance were prevented by all combination dosing schedules; however,
the simultaneous regimen consistently provided the greatest extent of killing for all strains,
particularly in those initially resistant to ciprofloxacin. These enhanced effects of the combina-
tion were corroborated by an increase in the peak and duration of bactericidal activity in the
analogous "serum" compartment of the model. These data show the potential usefulness of
simultaneous dosing of an antipseudomonal {j-lactam with ciprofloxacin against P. aeruginosa.
Several new fluoroquinolones have been developed that
have enhanced activity against gram-negative aerobic bacte-
ria. This enhanced in vitro activity has translated into clini-
cal efficacy in the treatment of selected infections [I]. Cipro-
floxacin is effective in the treatment of certain infections due
to Pseudomonas aeruginosa [I, 2]; however, clinical failures
and associated development of resistance during therapy
have occurred [3, 4]. These observations are consistent with
in vitro studies that demonstrate selection of fluoroquino-
lone-resistant bacterial subpopulations during drug exposure
[5, 6].
Antimicrobial combinations have been advanced as a
means to prevent the selection of drug-resistant organisms
during therapy for infection [7, 8]. Additive and even syner-
gistic activity between fluoroquinolones and ,B-Iactam antibi-
otics have been detected using classical in vitro methods [9-
11]. In view of these observations, the pharmacodynamics of
ciprofloxacin and azlocillin alone or in combination were
tested against four strains of P. aeruginosa with various de-
grees of susceptibility to each drug in an in vitro model of
infection. In addition, the influence of the timing of dosing
ofeach drug relative to another on bacterial killing was exam-
ined.
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Methods
Bacteria. Four stable clinical isolates of P. aeruginosa were
studied. Strains were selected on the basis of susceptibility to
ciprofloxacin and azlocillin such that all possible combinations
of susceptibility and resistance to one or both drugs would be
tested (i.e., resistant to ciprofloxacin, azlocillin, neither, or
both). Susceptibility testing was done using broth dilution in
cation-supplemented Mueller-Hinton (MHB-S) broth with an
inoculum of r-: 106 cfu/rnl using standardized methods [12, 13].
All strains were synergistically inhibited and killed by the drug
combination according to checkerboard synergism testing; the
fractional inhibitory (FIC) and fractional bactericidal concen-
tration (FBC) indices, respectively, were ~0.5 for all strains (ta-
ble 1).
In vitro model ofinfection and dosage regimens. The in vitro
model of infection used was a two-compartment system using
hollow fiber capillary units (Amicon, Danvers, MA) as previ-
ously described [14]. Briefly, each unit consists of a plastic tube
through which a bundle of polysulfone fibers is passed. Growth
medium containing drug is circulated through the lumen of the
fibers from a reservoir; this loop is the analogous "serum" or
central compartment. Medium isalso added to the chamber exte-
rior to the capillary fibers and inoculated with the organism to
be studied. The hollow fibers retain particles that are> 10,000
molecular weight; therefore, drug can diffuse to this analogous
"tissue" or peripheral compartment. Paired pharmacokinetic
(i.e., drug concentrations) and pharmacodynamic (i.e., bacterial
colony-forming units [cfuDobservations are made periodically
for these compartments. Drug concentrations are decayed from
the central compartment at a rate adjusted for pharmacokinetic
properties in humans by diluting the central reservoir with drug-
free medium.
Serum drug concentrations for intravenous (iv) doses ofcipro-
floxacin (200 mg, 3D-min infusion) [15] and azlocillin (4 g, iv
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Table 1. Antibiotic susceptibility and maximum bactericidal titer of Pseudomonasaeruginosa strains measured in the central compartment
of the in vitro model during the first 12 h.
MIC (MBC) in mg/l for Maximum titer (h of detectable bactericidal activity) for regimen
Strain Ciproftoxacin Azlocillin FIC FBC Ciproftoxacin Azlocillin C-OjA-O C-OjA-6 A-OjC-6
CsAs I (2) 32 (> 128) .19 .16 <1:2 (0) 1:8 (2) 1:8 (3) 1:8 (3) 1:4 (6)
CSAR I (2) 128 (>512) .31 .08 <1:2 (0) <1:2 (0) 1:8 (3) 1:2 (I) 1:2 (5)
CRAs 4 (8) 16(>128) .38 .25 <1:2 (0) 1:8 (3) 1:16(2) I: 16 (3) NO
CRAR 2 (2) 128 (> 1024) .38 .26 <1:2(0) <1:2 (0) 1:8 (3) 1:2 (5) 1:2 (4)
NOTE. FIe. fractional inhibitory concentration; FOe. fractional bactericidal concentration index; C-O/A-O, both drugs given simultaneously; C-OjA-6, ciprofloxacin
(C) given at 0 and 12 h, azlocillin (A) given at 6 and 18 h; A-OjC-6, A given at 0 and 12 h, C given at 6 and 18 h; S. susceptible; R, resistant; NO, not done.
bolus) [16] were simulated in the central compartment of the
model and were tested alone or in combination. The dosing
interval for each drug was 12 h when used alone or in combina-
tion.
Experiments were conducted with each drug alone and in
combination. Three strategies for administering the drugs in
combination were compared. Simultaneous administration of
both drugs at 0 and 12 h (C-O/A-O)or staggered administration
was tested. For staggered regimens, ciprofloxacin was given at 0
and 12 hand azlocillin at 6 and 18 h (C-0/A-6) or conversely
with azlocillin given first (A-0/C-6).
The bacterial inoculum was prepared from previously frozen
inocula by thawing, diluting with an equal part offresh MHB-S,
and incubating at 37°C for 1-2 h to bring organisms to the
log-linear growth phase. A sample ofthis mixture was then intro-
duced into the peripheral chambers of the model, which con-
tained 7-10 ml of MHB-S. Organisms were allowed to grow in
the chambers for -- I h to reach a final target inoculum of --2 X
106 cfu/ml,
Pharmacodynamic andpharmacokinetic measurements. Sam-
ples (0.5 ml) were collected from the peripheral chambers at
various times after drug administration to determine drug and
bacterial concentrations. Bacterial counts (cfu/ml) were deter-
mined by serial lO-fcld dilution of sample in cold saline and
inoculation (in triplicate) of 20 #II onto Mueller-Hinton agar
(MHA). Small numbers ofbacteria were counted by placing 100
#II of sample into --10 ml of cold saline and filtering this mix-
ture through a 0.45-#lm filter (Millipore, Bedford, MA). The
filter was then placed aseptically on drug-free MHA, incubated,
and the colonies counted. In selected experiments, samples col-
lected at 0, 12, and 24 h were also processed on MHA contain-
ing 1-8 mg/l of ciprofloxacin or 64-512 mg/l of azlocillin, re-
spectively, to detect drug-resistant bacterial subpopulations.
The limit for detection was 10 cfu/ml.
Samples in the peripheral and central compartments of the
model were assayed for ciprofloxacin and azlocillin using an
agar-well diffusion assay. Bacillus subtilis was used for measure-
ment of azlocillin concentrations; assay validation studies
showed no interference of this assay by up to 1.0 mg/l of cipro-
floxacin. Klebsiella pneumoniae ATCC 13883 was used in assays
for ciprofloxacin concentration; samples from combination ex-
periments with azlocillin were diluted with IHactamase (Difco,
Detroit) to prevent interference byazlocillin.
Samples from the central compartment were also assayed for
bactericidal activity against each organism. The microdilution
technique using MHB-S as the diluent was used for these studies
[17). Bacterial inocula were prepared from frozen samples as
described. Criteria for a bactericidal end point were those of
Pearson et al. [18].
Statistics. Differences between regimens in the change in log
cfu/rnl were compared using Peritz' F test [19]; two-tailed differ-
ences with a P < .05 (with adjustment for multiple comparisons)
were considered statistically significant.
Results
Pharmacokinetics
Figures I and 2 depict ciprofloxacin and azlocillin concen-
trations in the central and peripheral chambers ofthe model.
Mean peak ciprofloxacin concentrations in the central and
peripheral chambers after the first dose were 1.1 and 0.72
mg/l, respectively. The concentrations in the central com-
partment declined exponentially, with a 4-h half-life. Mean
peak azlocillin concentrations in the peripheral chambers oc-
curred at --2 h and averaged 102 mg/l. The half-life for
elimination of azlocillin from the central compartment was
1.2 h. As shown in figure 2, the C-O/A-O regimen resulted in
exposure of bacteria to high concentrations of both drugs
simultaneously followed by periods of low levels, whereas
staggered administration resulted in more sustained expo-
sure of bacteria to either drug.
Pharmacodynamics
The effects of single-drug and all combination treatments
on each strain are shown in figure 3. All organisms grew well
in the model during control experiments (no drug exposure).
Single-agent therapy. Rapid bacterial killing by ciproflox-
acin alone was observed in three offour strains; on average, a
2-3 log reduction in cfu/ml occurred within 6 h. In contrast,
no bacterial killing was observed with the strain most resis-
tant to ciprofloxacin (eRAs). After 4-6 h, bacterial regrowth
was observed with the other three strains; the second dose of
ciprofloxacin (at 12 h) had no effect on bacterial regrowth.
Analysis ofbacteria growing on MHA containing ciprofloxa-
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Figure 1. Concentrations of ciproflox-
acin (A) and azlocillin (B) in the central
and peripheral chambers of the model for
all experiments. Each point depicts mean
of 2-15 samples; bars indicate I SO.
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cin showed subpopulations resistant to peak or higher cipro-
floxacin concentrations by 12 and 24 h (figure 4).
In contrast to ciprofloxacin, azlocillin alone produced a
2-3 log reduction in cfu/rnl in all strains by 6 h (figure 3).
This period was followed by relative bacteriostasis in strains
initially susceptible (by MIC) to azlocillin. Bacterial strains
initially resistant to azlocillin (MIC >64 mg/l) had regrowth
patterns similar to that observed for ciprofloxacin: significant
growth (» 103 cfu/rnl) was observed on MHA containing 64-
256 mg/l ofazlocillin at 12 h, with 5-30 X 103 cfu/rnl resis-
tant to 512 mg/I by 24 h.
Combination therapy. The selection of ciprofloxacin- or
azlocillin-resistant bacteria was prevented by the combina-
tion of drugs. Only the staggered regimen of ciprofloxacin
followed by azlocillin (C-0/A-6) failed to kill the strain most
resistant to ciprofloxacin (CRAs, figure 3). For the strains
doubly susceptible or resistant to study drugs, simultaneous
administration resulted in enhanced bacterial killing by 6 h
over that observed with the staggered- or single-drug regi-
mens (P < .05). For the remaining two strains, the reduction
in cfu/milliliter by 6 h tended to reflect the activity of the
more active (based on MIC breakpoints) drug; thus, either
simultaneous or staggered dosing (with the more active drug
given first) produced results at 6 h, similar to that of the
active drug alone.
Analysis of bacterial killing by 12 h with the simultaneous
and staggered regimens allows for comparison of the cumula-
tive effects of the first doses of each drug. Simultaneous dos-
ing of ciprofloxacin plus azlocillin was superior to all single-
drug regimens (P < .05) except for azlocillin alone against
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Figure 2. Simulated and measured concentrations ofciprofloxa-
cin (C) and azlocillin (A) in the central compartment of the in vitro
model for simultaneous (C-OjA-O, top) and staggered with azlocil-
lin (A-OjC-6, middle) or ciprofloxacin (C-OjA-6, bottom) regimens
of the combination.
Discussion
liter but were superior (P < .05) to single drugs and the other
staggered (i.e., C-0/A-6) regimens.
Bactericidal activity. For the single-drug regimens, bacteri-
cidal activity in the central compartment was detected only
with azlocillin against strains susceptible to this drug (table
I). In contrast, all combination-drug regimens resulted in
detectable bactericidal activity. On average, the highest activ-
ity was observed when the combination was administered
simultaneously; however, staggered dosing provided more
prolonged periods of detectable bactericidal activity.
The design of the in vitro model allowed the use ofseveral
methods to evaluate the relation between the pharmacoki-
netic and pharmacodynamic properties ofeach drug alone or
in combination. The first dose of ciprofloxacin alone pro-
duced initial killing in three of four strains; the strain most
resistant to ciprofloxacin (CRAs• MIC = 4 mg/l) was not
killed by this drug. For the three other strains, a significant
(>3 log) reduction in cfu/milliliter was achieved during the
first 6 h of drug exposure; this occurred even though drug
concentrations in the peripheral compartment remained be-
low the MIC throughout the experiment. Similar to previous
reports [20], bacteria resistant to ciprofloxacin concentra-
tions achieved in the central and peripheral chambers were
clearly present in inocula recovered at 12 h, even for the two
strains initially susceptible to ciprofloxacin. Substantial ini-
tial bacterial killing with azlocillin was also observed in all
strains, even though concentrations in peripheral chambers
never exceeded the MIC for strains resistant to azlocillin
based on MIC criteria (i.e., CSAR and CRAR); however, re-
growth patterns similar to that observed with ciprofloxacin
alone occurred and persisted through subsequent doses of
azlocillin. In contrast, regrowth did not occur after the first
dose ofazlocillin with the strains initially susceptible to azlo-
cillin, even though concentrations were below the MIC by as
early as 6 h. These persistent inhibitory effects are consistent
with previous in vitro observations of bacterial growth sup-
pressed with subinhibitory drug concentrations after expo-
sure to high, suprainhibitory drug concentrations [21 ].
The advantage ofcombination therapy with these drugs in
our model was apparent by the lack of selection of ciproflox-
acin-resistant bacterial subpopulations. All combination regi-
mens resulted in a statistically significant greater reduction
in bacterial counts (>2 log cfu/ml) by 24 h than that seen
with single-drug regimens; these observations are compatible
with previous studies on synergistic drug interactions in this
model [22]. Notably, this enhanced effect was present in all
strains, including those resistant to one or both drugs, indi-
cating the potential clinical usefulness of this combination.
Previous studies of experimentally induced infections due
to P. aeruginosa in several animal models of infection have
variably demonstrated an advantage for combination ther-
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CsAs. For strains initially resistant to ciprofloxacin, simulta-
neous administration was superior to all other regimens (P <
.05).
In contrast to the first doses of each drug, the second 12-h
dosing cycle of all combination regimens was bacteriostatic;
the change in cfu/milliliter between 12 and 24 h ranged from
a reduction of 1.2 to an increase of 0.2 log cfu/ml in all
strains and combination regimens. Thus, the differences in
regimens were based on the extent of initial bacterial killing,
which was greatest when the combination was administered
simultaneously (i.e., C-O/A-O) for all strains. Reduction in
cfu/rnilliliter over 24 h was significantly greater for combina-
tion therapy using any dosing schedule against the two azlo-
cillin-susceptible and the doubly resistant strains than that
observed for single-drug therapies (P < .05); there were no
differences between simultaneous and staggered regimens
against the three strains (P > .05). For the strain with the
highest MIC to ciprofloxacin (i.e., CRAs), simultaneous and
staggered administration with azlocillin given first (i.e., C-O/
A-O and A-0/C-6) produced similar reductions in cfu/rnilli-
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Figure 3. Pharmacodynamics of five regimens of ciprofloxacin (C) and azlocillin (A) alone or in combination against four strains of
Pseudomonasaeruginosa. D, ciprofloxacin alone; +, azlocillin alone; 0, simultaneous ciprofloxacin plus azlocillin (C-OjA-O); D., X, staggered
ciproftoxacin plus azlocillin, with either ciproftoxacin (D., C-OjA-6) or azlocillin (X, A-OjC-6) given first. Each point depicts the mean of2-4
within or between day replications. Vertical lines at 6, 12, and 18 h identify dose events.
apy with a fluoroquinolone plus a JS-lactam [23-29]. The
benefit of adding azlocillin to ciprofloxacin therapy was par-
ticularly evident in studies using doses of ciprofloxacin that
resulted in low ratios of the peak drug concentration to the
MIC [23-26]; addition of azlocillin was associated with im-
proved bacterial killing [23, 24] or survival [25, 26] or sup-
pression of bacterial resistance to ciprofloxacin [23]. In con-
trast, other investigators concluded that adding an
antipseudomonal penicillin to ciprofloxacin was not advan-
tageous [27-29]. The discrepancies in outcome between dif-
ferent studies as well as those obtained in our model may
stem from differences in initial bacterial inoculums used (crit-
ical to include drug-resistant subpopulations) [6, 27], assess-
ment only of early bactericidal effects [29], or dosage regi-
mens that produced higher ciprofloxacin [28] or lower
JS-lactam concentrations [27] in animals than those obtained
in humans with usual doses. However, several examples of
clinical failure and the development offluoroquinolone resis-
tance during combination therapy with a JS-lactam have been
reported [30, 31].
In view of differences in pharmacokinetic and pharmaco-
dynamic properties between fluoroquinolones (longer elimi-
nation half-life, concentration-dependent killing, and post-
antibiotic effects) and ureidopenicillins (shorter elimination
half-life, lack of significant postantibiotic effect, or relation
between drug concentration and bacterial killing) [32], we
examined the effect of the timing of doses of each drug rela-
tive to another to analyze the effect of various drug concen-
trations (and ratios to each other) on bacterial killing and
regrowth. Simultaneous administration ofboth drugs was as-
sociated either with greater initial killing of bacteria over the
first 6 h or was similar to that observed for the more active
24
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Figure 4. Total bacterial counts and subpopulations resistant (R) to 1-8 mg/l of ciprofloxacin (C) in samples collected from peripheral
chamber of in vitro model at 0, 12, and 24 h after exposure to simulated doses of ciprofloxacin (200 mg iv) alone. A, azlocillin; S,
susceptible.
(based on MIC susceptibility criteria) drug alone. For the
strain most resistant to ciprofloxacin, simultaneous dosing of
the combination was critical because bacterial killing could
not be initiated with ciprofloxacin alone. Overall, simulta-
neous administration provided the most consistent bacteri-
cidal effects and did not vary according to the in vitro suscep-
tibility of each strain. Despite a significant reduction in
cfu/rnilliliter during the first dosing cycle for the simulta-
neous regimen, subsequent doses at or after 12 h for all stag-
gered regimens resulted only in bacteriostasis.
The importance oftiming ofdoses in use ofantibiotic com-
binations in the treatment of gram-negative bacillary infec-
tions has received little study. Bacterial killing with gentami-
cin and piperacillin in in vitro timed-kill curve experiments
was greatest when concentrations of each drug tested corre-
sponded to those after simultaneous administration of both
drugs [33]. In contrast, studies using in vitro kinetic models
of infection demonstrated greater killing of drug-susceptible
P. aeruginosa when the first dose of an aminoglycoside was
followed 2-4 h later by the first dose ofan antipseudomonal
penicillin [34, 35]; however, when azlocillin preceded the
first dose of sisomicin by 2 h, less killing was observed [34].
Recent studies using a model similar to that in the present
study with amikacin and ceftriaxone against ceftriaxone-
susceptible or -resistant strains of P. aeruginosa demon-
strated no significant differences in bacterial killing when
single daily doses were given alone or were staggered by 6 h
[36]. In contrast, simultaneous administration of ticarcillin
and gentamicin by continuous infusion compared with bolus
administration of one or both drugs resulted in more bacte-
rial killing and less mortality in rats infected with a strain of
P. aeruginosa resistant to both drugs but synergistically inhib-
ited [37]. These data and those from the current study sug-
gest the need for adequate contact time between drugs in
vivo for synergistic killing of drug-resistant bacteria.
Analysis of serum bactericidal titers on samples from the
central compartment confirmed previous in vivo observa-
tions on the poor serum bactericidal activity of iv doses of
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ciprofloxacin (200 mg) alone against P. aeruginosa [17] and
the additive or synergistic activity with azlocillin at clinically
relevant concentrations [38]. These measurements of the
central compartment of the model also provided some in-
sight into pharmacokinetic measurements linked to the ki-
netics of bacterial killing and the selection of bacterial resis-
tance. Simultaneous dosing of both drugs increased the
maximum bactericidal titer and the duration of detectable
bactericidal activity; increasing both the peak and duration
of effective drug concentrations would be expected to en-
hance the pharmacodynamic properties associated with ei-
ther drug alone. In contrast, staggered dosing of the two
drugs generally increased the duration, but not the intensity,
of activity. In view of the results from the peripheral
chambers of the model, these data confirm the concept that
high peak bactericidal activity early in the course of therapy
is important in the treatment of infections due to P. aerugi-
nosa with fluoroquinolones [25, 39, 40]. These data support
further clinical evaluation of these or higher doses of cipro-
floxacin combined with an antipseudornonal d-lactam in the
treatment of serious infections due to P. aeruginosa.
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